These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 17278373)

  • 1. Dysregulation of the gain of CICR through ryanodine receptor1 (RyR1): the putative mechanism underlying malignant hyperthermia.
    Ogawa Y
    Adv Exp Med Biol; 2007; 592():287-94. PubMed ID: 17278373
    [No Abstract]   [Full Text] [Related]  

  • 2. Postulated role of interdomain interaction between regions 1 and 2 within type 1 ryanodine receptor in the pathogenesis of porcine malignant hyperthermia.
    Murayama T; Oba T; Hara H; Wakebe K; Ikemoto N; Ogawa Y
    Biochem J; 2007 Mar; 402(2):349-57. PubMed ID: 17107340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defective Mg2+ regulation of RyR1 as a causal factor in malignant hyperthermia.
    Steele DS; Duke AM
    Arch Biochem Biophys; 2007 Feb; 458(1):57-64. PubMed ID: 16620769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic analysis with calcium-induced calcium release test in Japanese malignant hyperthermia susceptible (MHS) families.
    Maehara Y; Mukaida K; Hiyama E; Morio M; Kawamoto M; Yuge O
    Hiroshima J Med Sci; 1999 Mar; 48(1):9-15. PubMed ID: 10213958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional characterisation of the R2452W ryanodine receptor variant associated with malignant hyperthermia susceptibility.
    Roesl C; Sato K; Schiemann A; Pollock N; Stowell KM
    Cell Calcium; 2014 Sep; 56(3):195-201. PubMed ID: 25086907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody probe study of Ca2+ channel regulation by interdomain interaction within the ryanodine receptor.
    Kobayashi S; Yamamoto T; Parness J; Ikemoto N
    Biochem J; 2004 Jun; 380(Pt 2):561-9. PubMed ID: 15027895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergent effects of the malignant hyperthermia-susceptible Arg(615)-->Cys mutation on the Ca(2+) and Mg(2+) dependence of the RyR1.
    Balog EM; Fruen BR; Shomer NH; Louis CF
    Biophys J; 2001 Oct; 81(4):2050-8. PubMed ID: 11566777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Divergent Activity Profiles of Type 1 Ryanodine Receptor Channels Carrying Malignant Hyperthermia and Central Core Disease Mutations in the Amino-Terminal Region.
    Murayama T; Kurebayashi N; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
    PLoS One; 2015; 10(6):e0130606. PubMed ID: 26115329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in RYR1 in malignant hyperthermia and central core disease.
    Robinson R; Carpenter D; Shaw MA; Halsall J; Hopkins P
    Hum Mutat; 2006 Oct; 27(10):977-89. PubMed ID: 16917943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased sensitivity of the ryanodine receptor to halothane-induced oligomerization in malignant hyperthermia-susceptible human skeletal muscle.
    Glover L; Heffron JJ; Ohlendieck K
    J Appl Physiol (1985); 2004 Jan; 96(1):11-8. PubMed ID: 12959958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular Ca2+ dynamics in malignant hyperthermia and central core disease: established concepts, new cellular mechanisms involved.
    Avila G
    Cell Calcium; 2005 Feb; 37(2):121-7. PubMed ID: 15589992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA.
    Sato K; Pollock N; Stowell KM
    Anesthesiology; 2010 Jun; 112(6):1350-4. PubMed ID: 20461000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant hyperthermia mutation sites in the Leu2442-Pro2477 (DP4) region of RyR1 (ryanodine receptor 1) are clustered in a structurally and functionally definable area.
    Bannister ML; Hamada T; Murayama T; Harvey PJ; Casarotto MG; Dulhunty AF; Ikemoto N
    Biochem J; 2007 Jan; 401(1):333-9. PubMed ID: 16958617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutated p.4894 RyR1 function related to malignant hyperthermia and congenital neuromuscular disease with uniform type 1 fiber (CNMDU1).
    Haraki T; Yasuda T; Mukaida K; Migita T; Hamada H; Kawamoto M
    Anesth Analg; 2011 Dec; 113(6):1461-7. PubMed ID: 21926372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of ryanodine receptors.
    Ogawa Y
    Crit Rev Biochem Mol Biol; 1994; 29(4):229-74. PubMed ID: 8001396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A SNO storm in skeletal muscle.
    Stamler JS; Sun QA; Hess DT
    Cell; 2008 Apr; 133(1):33-5. PubMed ID: 18394987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular pathology of malignant hyperthermia and central core disease].
    Takagi A
    Nihon Rinsho; 1997 Dec; 55(12):3307-14. PubMed ID: 9436456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unravelling calcium-release channel gating: clues from a 'hot' disease.
    McCarthy TV; Mackrill JJ
    Biochem J; 2004 Jun; 380(Pt 2):e1-3. PubMed ID: 15154833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors.
    Censier K; Urwyler A; Zorzato F; Treves S
    J Clin Invest; 1998 Mar; 101(6):1233-42. PubMed ID: 9502764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal muscle ryanodine receptor mutations associated with malignant hyperthermia showed enhanced intensity and sensitivity to triggering drugs when expressed in human embryonic kidney cells.
    Sato K; Roesl C; Pollock N; Stowell KM
    Anesthesiology; 2013 Jul; 119(1):111-8. PubMed ID: 23459219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.